← Leaderboards
Mary Beth Humphrey
Oklahoma City Va Medical Center
$4,331,907
Attributed
$7,974,195
Total exposure
10
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.8M · FY2007–25$5M$3.8M$2.5M$1.3M$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,974,195 · 8
VA$0 · 2
By mechanism
RF1$3,909,100 · 1
R01$3,348,422 · 2
P20$716,673 · 5
I01$0 · 1
IS1$0 · 1
Top collaborators
- Leonidas Tsiokas5 shared
- Steven Estus2 shared
- William Garrow Kerr2 shared
Others in their field
Top investigators on “Signal Transduction”
- Peter B. Gilbert · Fred Hutchinson Cancer Center$148,539,615
- David Heimbrook · Leidos Biomedical Research, Inc.$82,049,940
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$70,290,471
- Garret A Fitzgerald · University Of Pennsylvania$66,142,222
- Michael Barry Kastan · Duke University$64,512,357
- Randall J Bateman · Washington University$62,939,456
Research focus
Signal TransductionResponseCellsPathway InteractionsOsteoclastsIn VitroProteinsMediatingBoneOsteoclastogenesisRegulationAffectReceptorIn VivoTnfsf11 GeneNovel Therapeutic InterventionLeadMolecularBaseBone RemodelingOsteoporosisRheumatoid ArthritisBone ResorptionMacrophage
Grant awards (21)
BCCMA: Targeting Osteoarthritis Pain and Progression: Preclinical OA models of vagal nerve stimulation to reduce pain and progression of OA$0
I01 · FY2025 · VA · contact PI
BCCMA: Targeting Osteoarthritis Pain and Progression: Preclinical OA models of vagal nerve stimulation to reduce pain and progression of OA$0
I01 · FY2024 · VA · contact PI
BCCMA: Targeting Osteoarthritis Pain and Progression: Preclinical OA models of vagal nerve stimulation to reduce pain and progression of OA$0
I01 · FY2023 · VA · contact PI
ShEEP Request for SCANCO microCT$0
IS1 · FY2023 · VA · contact PI
Translating SHIP1 Genetics to Generate a Novel Alzheimers Pharmacologic Agent$118,080
RF1 · FY2019 · AG
Translating SHIP1 genetics to generate a novel Alzheimer's pharmacologic agent$3,791,020
RF1 · FY2018 · AG
Calcium Regulation in Osteoclasts$410,984
R01 · FY2017 · AR
Calcium Regulation in Osteoclasts$410,984
R01 · FY2016 · AR
Calcium Regulation in Osteoclasts$410,984
R01 · FY2015 · AR
Calcium Regulation in Osteoclasts$422,968
R01 · FY2014 · AR
Calcium Regulation in Osteoclasts$416,522
R01 · FY2013 · AR
Mechanism of ITAM Signal Regulation in Osteoclasts$252,092
R01 · FY2012 · DE · contact PI
Mechanism of ITAM Signal Regulation in Osteoclasts$246,968
R01 · FY2011 · DE · contact PI
UNDERSTANDING THE ROLE OF ALTERNATIVE SPLICING IN THE TNFAIP3 SLE-RISK ALLELES$172,201
P20 · FY2011 · RR · contact PI
Mechanism of ITAM Signal Regulation in Osteoclasts$254,576
R01 · FY2010 · DE · contact PI
UNDERSTANDING THE ROLE OF ALTERNATIVE SPLICING IN THE TNFAIP3 SLE-RISK ALLELES$240,501
P20 · FY2010 · RR · contact PI
Mechanism of ITAM Signal Regulation in Osteoclasts$259,201
R01 · FY2009 · DE · contact PI
SHIP1 REGULATION OF DAP12 IN OSTEOCLAST DEVELOPMENT AND FUNCTION$96,571
P20 · FY2009 · RR · contact PI
Mechanism of ITAM Signal Regulation in Osteoclasts$263,143
R01 · FY2008 · DE · contact PI
SHIP1 REGULATION OF DAP12 IN OSTEOCLAST DEVELOPMENT AND FUNCTION$105,291
P20 · FY2008 · RR · contact PI
SHIP1 REGULATION OF DAP12 IN OSTEOCLAST DEVELOPMENT AND FUNCTION$102,109
P20 · FY2007 · RR · contact PI